Using retinol with minoxidil may not be as effective as tretinoin, but retinaldehyde or adapalene could be alternatives. A micro-roller with minoxidil is suggested for better results.
The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.
A 24-year-old with hair thinning is using a regimen including dutasteride, RU58841, HGH, GHK-cu, and other compounds to protect and regrow hair. They are also incorporating a mild cutting cycle with testosterone propionate, anavar, and tirzepatide.
2-deoxy-D-ribose, a sugar molecule, is found to be 80%-90% as effective as Minoxidil in promoting hair growth, showing potential for alopecia treatment. Concerns include high cost, lack of human studies, and possible side effects like diarrhea and nausea.
Hair loss treatments discussed include microneedling, minoxidil, tretinoin, finasteride, dutasteride, pumpkin seeds, saw palmetto, and scalp massage. The consensus is that finasteride or dutasteride is necessary for significant regrowth, while other methods may only slow hair loss.
Topical Dutasteride is more effective than topical Finasteride for treating AGA in men, with fewer side effects. Mesotherapy with Dutasteride, administered every 3 months, shows promising results for hair regrowth and maintenance without daily routines or significant side effects.
The conversation discusses the effectiveness of finasteride and microneedling for treating hair loss. The linked article is seen as an advertisement for these treatments.
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
The conversation is about a hair loss treatment regimen that includes finasteride, dutasteride, oral minoxidil, Dermapen, quercetin, N-acetyl L-cysteine, biotin, millet seed extract, MSM, OPC, green tea extract, high-dose vitamins B1-B12, boron, and silica. The user is seeking advice on additional treatments.
A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.
A user shared their pre-finasteride lab results, including DHT, estradiol, testosterone, SHBG, prolactin, FSH, and LH levels. Another user responded, cautioning against making unsupported claims about side effects and recovery.
User started DUT 3 times a week, topical minoxidil/tretinoin at night, and topical stemoxydine/alfatradiol mix with tretinoin in the morning for hair loss. They experienced significant progress and no side effects, crediting a YouTuber for encouragement.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
A user shared progress pictures 1.5 months after a hair transplant of 3500 grafts, using oral finasteride, topical finasteride, minoxidil, and vitamins. They are concerned about potential shock loss and the thinning appearance.
The user is considering switching from a 5% minoxidil and 0.1% finasteride mix to a combination of 5% minoxidil, 0.1% finasteride, 0.01% tretinoin, and 1.5% azelaic acid due to low regrowth success. They are seeking advice on whether to use the new mix at night and continue the old mix in the morning or try oral minoxidil in the morning.
The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.
A woman with AGA and CTE has been taking multiple hair loss treatments including spironolactone, dutasteride, finasteride, bicalutamide, birth control, and minoxidil without success. Steroid injections, however, dramatically and immediately stopped her hair loss, though the effect lasts less than a month.
The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.
MSM is discussed as a potential treatment for hair regrowth, with mixed opinions on its effectiveness. Some users report faster hair and nail growth, while others question its credibility due to lack of scientific evidence.
The user is excited about starting Clascoterone 5% for hair loss, a DHT blocker, and expects better results when combined with Minoxidil. The prescription costs $199 for 30 ml or $353 for 60 ml, and the user plans to cover the cost by driving for Uber.
Dutasteride is more effective than finasteride, has neuroprotective benefits, and may prevent acne. Despite initial concerns about metabolic effects, further research suggests it is safe for most users, especially if not hypogonadal.
P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.